These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 29783157)

  • 1. Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder.
    Mealy MA; Cook LJ; Pache F; Velez DL; Borisow N; Becker D; Arango JAJ; Paul F; Levy M
    Mult Scler Relat Disord; 2018 Jul; 23():78-82. PubMed ID: 29783157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
    Kitley J; Leite MI; Nakashima I; Waters P; McNeillis B; Brown R; Takai Y; Takahashi T; Misu T; Elsone L; Woodhall M; George J; Boggild M; Vincent A; Jacob A; Fujihara K; Palace J
    Brain; 2012 Jun; 135(Pt 6):1834-49. PubMed ID: 22577216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders.
    Mealy MA; Kim SH; Schmidt F; López R; Jimenez Arango JA; Paul F; Wingerchuk DM; Greenberg BM; Kim HJ; Levy M
    Mult Scler; 2018 Nov; 24(13):1737-1742. PubMed ID: 28857723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis.
    Kong L; Wang X; Chen H; Shi Z; Lang Y; Zhang Y; Zhou H
    Mult Scler Relat Disord; 2022 Dec; 68():104167. PubMed ID: 36170773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
    Collongues N; Marignier R; Jacob A; Leite MI; Siva A; Paul F; Zephir H; Akman-Demir G; Elsone L; Jarius S; Papeix C; Mutch K; Saip S; Wildemann B; Kitley J; Karabudak R; Aktas O; Kuscu D; Altintas A; Palace J; Confavreux C; De Seze J
    Mult Scler; 2014 Jul; 20(8):1086-94. PubMed ID: 24323817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study.
    Kessler RA; Mealy MA; Jimenez-Arango JA; Quan C; Paul F; López R; Hopkins S; Levy M
    Mult Scler Relat Disord; 2017 Oct; 17():198-201. PubMed ID: 29055457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder.
    Shimizu Y; Fujihara K; Ohashi T; Nakashima I; Yokoyama K; Ikeguch R; Takahashi T; Misu T; Shimizu S; Aoki M; Kitagawa K
    Mult Scler; 2016 Oct; 22(11):1413-1420. PubMed ID: 25921053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica.
    Viswanathan S; Wong AH; Quek AM; Yuki N
    J Neuroimmunol; 2015 May; 282():92-6. PubMed ID: 25903734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of neuromyelitis optica spectrum disorder following seasonal influenza vaccination.
    Cho JH; Park Y; Woo N
    Mult Scler Relat Disord; 2019 May; 30():110-113. PubMed ID: 30769255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of neuromyelitis optica spectrum disorder attacks in different age groups and sexes depending on the status of immunosuppressive therapy: A retrospective cohort study.
    Luo W; Shi Z; Kong L; Wang X; Zhou H
    Eur J Neurol; 2024 Mar; 31(3):e16178. PubMed ID: 38117536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: Results from a Japanese claims database.
    Nakashima I; Nakahara J; Yasunaga H; Yamashita M; Nishijima N; Satomura A; Nio M; Fujihara K
    Mult Scler Relat Disord; 2024 Apr; 84():105502. PubMed ID: 38401202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Characteristics of Patients With Neuromyelitis Optica Spectrum Disorders With Early Onset.
    Fragoso YD; Sousa NAC; Saad T; Alves-Leon SV; Pimentel MLV; Goncalves MVM; Stella CV; Diniz DS; Santos GC; Gomes S; Adoni T; Anacleto A; Claudino R; Malfetano FR; Winckler TCD; Damasceno A; Eboni ACB; Farinhas JGD; Mota RSS
    J Child Neurol; 2019 Aug; 34(9):487-490. PubMed ID: 31012355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study.
    Ayzenberg I; Schöllhammer J; Hoepner R; Hellwig K; Ringelstein M; Aktas O; Kümpfel T; Krumbholz M; Trebst C; Paul F; Pache F; Obermann M; Zeltner L; Schwab M; Berthele A; Jarius S; Kleiter I;
    J Neurol; 2016 Mar; 263(3):575-82. PubMed ID: 26810718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.
    Stellmann JP; Krumbholz M; Friede T; Gahlen A; Borisow N; Fischer K; Hellwig K; Pache F; Ruprecht K; Havla J; Kümpfel T; Aktas O; Hartung HP; Ringelstein M; Geis C; Kleinschnitz C; Berthele A; Hemmer B; Angstwurm K; Young KL; Schuster S; Stangel M; Lauda F; Tumani H; Mayer C; Zeltner L; Ziemann U; Linker RA; Schwab M; Marziniak M; Then Bergh F; Hofstadt-van Oy U; Neuhaus O; Zettl U; Faiss J; Wildemann B; Paul F; Jarius S; Trebst C; Kleiter I;
    J Neurol Neurosurg Psychiatry; 2017 Aug; 88(8):639-647. PubMed ID: 28572277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic options in neuromyelitis optica spectrum disorders.
    Kitley J; Palace J
    Expert Rev Neurother; 2016; 16(3):319-29. PubMed ID: 26840802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
    Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH
    Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies.
    Kim SH; Jang H; Park NY; Kim Y; Kim SY; Lee MY; Hyun JW; Kim HJ
    Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33622675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.
    Kitley J; Elsone L; George J; Waters P; Woodhall M; Vincent A; Jacob A; Leite MI; Palace J
    J Neurol Neurosurg Psychiatry; 2013 Aug; 84(8):918-21. PubMed ID: 23467418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent optic neuritis and neuromyelitis optica-IgG following first and second human papillomavirus vaccinations.
    Chang H; Lee HL; Yeo M; Kim JS; Shin DI; Lee SS; Lee SH
    Clin Neurol Neurosurg; 2016 May; 144():126-8. PubMed ID: 27046292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder.
    Ringelstein M; Ayzenberg I; Harmel J; Lauenstein AS; Lensch E; Stögbauer F; Hellwig K; Ellrichmann G; Stettner M; Chan A; Hartung HP; Kieseier B; Gold R; Aktas O; Kleiter I
    JAMA Neurol; 2015 Jul; 72(7):756-63. PubMed ID: 25985228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.